Last reviewed · How we verify

NCT04594408

Tranexamic Acid to Improve Arthroscopic Visualization in Shoulder Surgery

Completed Phase 4 Last updated 2 April 2024
What this trial tests

Phase 4 trial testing Epinephrine in Rotator Cuff Injuries in 128 participants. Completed in 1 January 2024.

Timeline
1 September 2020
Primary endpoint
1 October 2021
1 January 2024

Quick facts

Lead sponsorPanam Clinic
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment128
Start date1 September 2020
Primary completion1 October 2021
Estimated completion1 January 2024
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Panam Clinic

Who can join

18 and older, any sex, with Rotator Cuff Injuries or Rotator Cuff Tears. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine if intravenous TXA is a safe alternative to epinephrine in improving arthroscopic shoulder visualization. Primary Objectives 1. Determine that patients given intravenous tranexamic acid improves surgeon-rated visualization compared to placebo. 2. Determine that intravenous tranexamic acid is a safe alternative to epinephrine mixed irrigation fluid to improve arthroscopic shoulder visualization

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Epinephrine

Trials testing the same drug.

Other recruiting trials for Rotator Cuff Injuries

Currently open trials in the same condition.

Other Panam Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04594408.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing